Clinical trial · Interventional
Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer
NCT03611179CI-TRIAL-00034110unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Our study aims at assessment of response, survival and toxicity of frontline treatment with chemotherapy and Bevacizumab in patients having advanced epithelial ovarian cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bevacizumab | Drug | Bevacizumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- advanced ovarian cancer cases
- description
- patients with advanced ovarian cancer will receive Bevacizumab 15 mg/kg every 21 days with chemotherapy (Paclitaxel 175 mg/m2 \& Carboplatin AUC 5 every 21 days)
- interventionNames
- Drug: Bevacizumab
Primary outcomes (1)
- measure
- progression free survival
- timeFrame
- 2 years
- description
- determination of time from starting treatment until first progression
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Female patients diagnosed with advanced ovarian cancer by biopsy * Age more than 18 years old * Routine labs are within normal values ( CBC, renal function tests , liver function tests ) * Performance score 0-2 * FIGO stage II-IV * Not having any contraindication to bevacizumab as : uncontrolled hypertension , bleeding tendency , ischaemic events * Chemotherapy naïve. * Informed consent Exclusion Criteria: * patients previously received chemotherapy or radiotherapy to any part of the abdomen or pelvis * patients with uncontrolled infection * patients with clinically significant cardiovascular disease * patients with active bleeding or conditions associated with high risk of bleeding * patients with history of CNS disease
References
Publications (3)
- BACKGROUNDSiegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7. PMID 26742998
- BACKGROUNDAarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, Peltomaki P, Mecklin JP, Jarvinen HJ. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 1999 Apr 12;81(2):214-8. doi: 10.1002/(sici)1097-0215(19990412)81:23.0.co;2-l. PMID 10188721
- BACKGROUNDWright AA, Cronin A, Milne DE, Bookman MA, Burger RA, Cohn DE, Cristea MC, Griggs JJ, Keating NL, Levenback CF, Mantia-Smaldone G, Matulonis UA, Meyer LA, Niland JC, Weeks JC, O'Malley DM. Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer. J Clin Oncol. 2015 Sep 10;33(26):2841-7. doi: 10.1200/JCO.2015.61.4776. Epub 2015 Aug 3. PMID 26240233